Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia's perspective.
Alakeel YS, Rampakakis E, AlRumaih A, AlRuwaisan R, Abushal M, AlDalaan AM, Idrees MM, Alanazi ZD, AlKoait H, Muaadi A, AlAfra MAM, AlShaya SA, AlHomida S. Alakeel YS, et al. Among authors: rampakakis e. Front Pharmacol. 2024 Apr 18;15:1376009. doi: 10.3389/fphar.2024.1376009. eCollection 2024. Front Pharmacol. 2024. PMID: 38698816 Free PMC article.
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
Coates LC, Gossec L, Zimmermann M, Shawi M, Rampakakis E, Shiff NJ, Kollmeier AP, Xu XL, Nash P, Mease PJ, Helliwell PS. Coates LC, et al. Among authors: rampakakis e. RMD Open. 2024 Mar 26;10(1):e003977. doi: 10.1136/rmdopen-2023-003977. RMD Open. 2024. PMID: 38531621 Free PMC article. Clinical Trial.
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study.
Coates LC, Rahman P, Mease PJ, Shawi M, Rampakakis E, Kollmeier AP, Xu XL, Chakravarty SD, McInnes IB, Tam LS. Coates LC, et al. Among authors: rampakakis e. BMC Rheumatol. 2024 Feb 4;8(1):6. doi: 10.1186/s41927-024-00375-w. BMC Rheumatol. 2024. PMID: 38310261 Free PMC article.
Feasibility and Safety of Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia (SANE-01): A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Trial.
Wintermark P, Lapointe A, Steinhorn R, Rampakakis E, Burhenne J, Meid AD, Bajraktari-Sylejmani G, Khairy M, Altit G, Adamo MT, Poccia A, Gilbert G, Saint-Martin C, Toffoli D, Vachon J, Hailu E, Colin P, Haefeli WE. Wintermark P, et al. Among authors: rampakakis e. J Pediatr. 2024 Mar;266:113879. doi: 10.1016/j.jpeds.2023.113879. Epub 2023 Dec 22. J Pediatr. 2024. PMID: 38142044 Free article. Clinical Trial.
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.
Colmegna I, Valerio V, Amiable N, Useche M, Rampakakis E, Flamand L, Rollet-Labelle E, Bessette L, Fitzcharles MA, Hazel E, McCormack D, Michou L, Panopalis P, Langlois MA, Bernatsky S, Fortin PR. Colmegna I, et al. Among authors: rampakakis e. RMD Open. 2023 Nov 29;9(4):e003400. doi: 10.1136/rmdopen-2023-003400. RMD Open. 2023. PMID: 38030231 Free PMC article. Clinical Trial.
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
Mease PJ, Gottlieb AB, Ogdie A, McInnes IB, Chakravarty SD, Rampakakis E, Kollmeier A, Xu XL, Shawi M, Lavie F, Kishimoto M, Rahman P. Mease PJ, et al. Among authors: rampakakis e. Clin Rheumatol. 2024 Jan;43(1):241-249. doi: 10.1007/s10067-023-06745-y. Epub 2023 Oct 3. Clin Rheumatol. 2024. PMID: 37787903 Free PMC article. Clinical Trial.
116 results